Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:21 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 1,709 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infection (HIV) Clear all
Completed Phase 2 Interventional

The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

NCT00002347
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Nevirapine, Zidovudine, Zalcitabine
Drug
Lead sponsor
Parexel
Industry
Eligibility
13 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 1 Interventional

Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus

NCT00503347
View directory record Official record
Conditions
Hepatitis C Virus, Hiv Infections
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 2 Interventional

Risk Reduction for Urban Substance Using Men Who Have Sex With Men (MSM)

NCT01327898
View directory record Official record
Conditions
HIV Infection, Substance Abuse
Interventions
empowerment theory-based small group discussion, individual resilience counseling
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Miami Beach, Florida • Wilton Manors, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Nov 2, 2026, 9:21 PM EST
Terminated Phase 2 Interventional Results available

Aspirin and Antiretroviral Therapy in HIV Infected Patients

NCT00783614
View directory record Official record
Conditions
HIV Infection
Interventions
Aspirin 325mg, Antiretroviral therapy (ART)
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Nov 2, 2026, 9:21 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The OPENS Trial: Offering Women PrEP (Aim 2)

NCT05619497
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Immunodeficiency Virus Transmission, Sexually Transmitted Diseases
Interventions
Clinic-wide Trainings, Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST), Standard Care with the HIV Prevention Decision Support Tool (DST)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Nov 2, 2026, 9:21 PM EST
Completed Not applicable Interventional

The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients

NCT00001023
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Azithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
11
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Nov 2, 2026, 9:21 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Project PRIDE (Promoting Resilience In Discriminatory Environments)

NCT03528135
View directory record Official record
Conditions
Human Immunodeficiency Virus, Sexually Transmitted Infections, Anxiety, Depression, Substance Use Disorders
Interventions
Project PRIDE
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 25 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Nov 2, 2026, 9:21 PM EST
Recruiting Phase 1 Interventional

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

NCT06819176
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Lenacapavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 3 Interventional Results available

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

NCT00524368
View directory record Official record
Conditions
Human Immunodeficiency Virus - Type 1
Interventions
Darunavir (DRV), Ritonavir (rtv)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Nov 2, 2026, 9:21 PM EST
Recruiting Not applicable Interventional

Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)

NCT05136703
View directory record Official record
Conditions
Depression, HIV-1-infection, Inflammation
Interventions
Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD), Antiretroviral Therapy (ART) Adherence Counseling
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 2 Interventional

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

NCT00634959
View directory record Official record
Conditions
HIV
Interventions
Maraviroc (UK-427,857), Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 3 Interventional Results available

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

NCT00460746
View directory record Official record
Conditions
HIV
Interventions
TMC125, Darunavir; Ritonavir
Drug
Lead sponsor
Tibotec, Inc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Nov 2, 2026, 9:21 PM EST
Recruiting Not applicable Interventional

Human Immunodeficiency Virus (HIV) Food Insecurities

NCT04943861
View directory record Official record
Conditions
Food Insecurities, Cardiometabolic Comorbidities, HIV, PreDiabetes, Type 2 Diabetes Mellitus (T2DM)
Interventions
weCare/Secure, Usual Care
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 1 Interventional

The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients

NCT00001074
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
18
States / cities
San Diego, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

NCT02469246
View directory record Official record
Conditions
HIV-1 Infection
Interventions
F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
34
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 2Phase 3 Interventional Results available

Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

NCT02859961
View directory record Official record
Conditions
HIV
Interventions
PRO 140 (350 mg), PRO 140 (525 mg), PRO 140 (700 mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
La Mesa, California • Palm Springs, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 1 Interventional

Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women

NCT00006320
View directory record Official record
Conditions
HIV Infection
Interventions
determine blood levels of anti-HIV drugs
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 2, 2026, 9:21 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Juvenile Detention to Community Life

NCT01910324
View directory record Official record
Conditions
Substance Use, Delinquency, Risk for HIV Infection
Interventions
Multidimensional Family Therapy Cross-Systems, Enhanced Services as Usual
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
13 Years to 17 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
5
States / cities
Clearwater, Florida • Largo, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Nov 2, 2026, 9:21 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health

NCT06796686
View directory record Official record
Conditions
HIV
Interventions
426c.Mod.Core-C4b, HxB2.WT.Core-C4b, 3M-052-AF adjuvant, Aluminum hydroxide suspension (Alum) adjuvant, Diluent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
San Francisco, California • Atlanta, Georgia • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 2 Interventional

A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

NCT00002169
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Orange, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 9:21 PM EST
Completed Not applicable Interventional

An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

NCT00002205
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 9:21 PM EST
Completed No phase listed Observational

A Study of Patients With AIDS Syndrome

NCT00001120
View directory record Official record
Conditions
Sarcoma, Kaposi, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, AIDS-Related
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Menlo Park, California • San Francisco, California • San Rafael, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2008 · Synced Nov 2, 2026, 9:21 PM EST
Not listed Phase 2 Interventional

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

NCT00299897
View directory record Official record
Conditions
HIV Infections, Human Immunodeficiency Virus
Interventions
SP01A
Drug
Lead sponsor
Samaritan Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2006 · Synced Nov 2, 2026, 9:21 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

GSK706769 Repeat Dose Study

NCT00711386
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK706769, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Nov 2, 2026, 9:21 PM EST